Zylox, GL Capital to Invest HK$1.48B in LifeTech Pending Conditions
LifeTech Scientific announced on November 6, 2026 that Zylox-Tonbridge Medical Technology and GL Capital had conditionally agreed to an approximately HK$1.48 billion subscription for new LifeTech shares. The proposed investment establishes an initial step toward a broader vascular and structural-heart intervention platform. Their joint vehicle, GL Lighthouse Two Investment Limited, would subscribe for 926,342,480 shares at HK$1.60 each. A transaction filing puts that at 20.0% of LifeTech's…